Real-world use of neratinib as extended adjuvant therapy in HER2-positive early-stage breast cancer (EBC): A multicentre study in China

Kadcyla (ado-trastuzumab emtansine) - Roche

Nerlynx (neratinib) - Puma

Perjeta (pertuzumab) - Roche

https://oncologypro.esmo.org/congress-resources/esmo-breast-cancer-2026?presentation=real_world_use_of_neratinib_as_extended_adjuvant_t

N. Abudureheiyimu1; Y. Jia2; Z. Peng2; Y. Shi3; Q. Liu4; H. Wang5; Y. Zhou6; H. Wang7; K. Wang8; H. Hu9; Z. Liu10; W. Chen11; T. Ng12; Z. Guo13; Z. Ren13; H. Zhen13; F. Ying2; B. Xu2

Feb 25, 2026